ESMO 2016 Congress

Oncology Meeting Resources

07 Oct - 11 Oct 2016, Copenhagen, Denmark

ESMO-Congress-2016-square

The annual ESMO congress is the premier scientific platform to present your oncology research and as such, the ultimate learning experience for congress attendees. Find the abstracts, posters, PDF presentation and webcasts from ESMO 2016 to the extent the presenters have consented to release their contribution or a slightly modified version thereof. Please, note that the publication of these presentations is a courtesy of the originating authors and is for personal educational purposes only.

Special Sessions and Tracks

Useful links





Format available

https://oncologypro.esmo.org/Meeting-Resour...tic-cancer-PC-Younger-vs.-older-patients-pts

BackgroundThere is limited data on molecular tumor characteristics and outcome in younger pts with PC. The effect of an individual's age on their tumor molecular profile is unknown.

Date: 08 Oct 2016
Presenter: Mohamed Salem
Resources: Abstract
Topics: Pancreatic Cancer, Translational Research, Basic Principles in the Management and Treatment (of cancer)

https://oncologypro.esmo.org/Meeting-Resour...eatic-cancer-LAPC-Final-analysis-of-JCOG1106

BackgroundJCOG1106 is a phase II trial to evaluate the efficacy and safety of chemoradiotherapy (CRT) with and without induction chemotherapy (CT) to determine which is more promising CRT regimen for LAPC.

Date: 08 Oct 2016
Presenter: Tatsuya Ioka
Resources: Abstract
Topics: Anticancer Agents, Pancreatic Cancer, Surgical Oncology, Therapy, Biological Therapy, Radiation Oncology

https://oncologypro.esmo.org/Meeting-Resour...ously-treated-with-gemcitabine-based-therapy

Backgroundnal-IRI, a liposomal formulation of irinotecan, plus 5-FU/LV is approved in the US for patients (pts) with mPAC previously treated with gemcitabine-based therapy.

Date: 08 Oct 2016
Presenter: Li-Tzong Chen
Resources: Abstract
Topics: Anticancer Agents, Pancreatic Cancer, Therapy, Biological Therapy

https://oncologypro.esmo.org/Meeting-Resour...-response-rate-in-stage-IV-pancreatic-cancer

BackgroundPancreatic cancer has a current five-year survival rates of less than 10%. Current standard treatment is combination chemotherapy with FOLFIRINOX or Gemcitabine + Abraxane.

Date: 08 Oct 2016
Presenter: Angela Alistar
Resources: Abstract
Topic: Pancreatic Cancer

https://oncologypro.esmo.org/Meeting-Resour...n-European-database-and-real-life-evaluation

BackgroundFor a long time gemcitabine (gem) has been the standard of care for patients with pancreatic ductal adenocarcinoma (PDAC). Recently, FOLFIRINOX and nab-paclitaxel/gemcitabine (nab-P/gem) were...

Date: 08 Oct 2016
Presenter: Sebastian Krug
Resources: Abstract
Topic: Pancreatic Cancer

https://oncologypro.esmo.org/Meeting-Resour...usly-untreated-stage-IV-pancreatic-cancer-PC

BackgroundVAN is a first-in-class antibody that blocks WNT signaling by interacting with 5 Frizzled receptors (1, 2, 5, 7, 8). VAN, with Nab-P and G, was very effective in causing tumor regression in pt-derived PC xenografts.

Date: 08 Oct 2016
Presenter: Wells Messersmith
Resources: Abstract
Topic: Pancreatic Cancer

https://oncologypro.esmo.org/Meeting-Resour...apanese-patients-pts-JASPAC-06-final-results

BackgroundFor Japanese pts, there are limited data of a small phase II trial of FFX (Okusaka, Cancer Sci 2014). In this multi-center retrospective study, we previously reported the preliminary results...

Date: 08 Oct 2016
Presenter: Nobumasa Mizuno
Resources: Abstract
Topic: Pancreatic Cancer

https://oncologypro.esmo.org/Meeting-Resour...inox-in-metastatic-pancreatic-adenocarcinoma

BackgroundFolfirinox (FFX) and Nab-paclitaxel/Gemcitabine (AG) showed significant improvement in efficacy compared to Gemcitabine alone in metastatic pancreatic cancer (mPC).

Date: 08 Oct 2016
Presenter: Eric Assenat
Resources: Abstract
Topic: Pancreatic Cancer

https://oncologypro.esmo.org/Meeting-Resour...survival-for-patients-with-pancreatic-cancer

BackgroundPrevious epidemiological studies have shown that diabetes mellitus (DM), alcohol, smoking and pancreatic cancer (PC) in close relatives are risk factors for developing PC.

Date: 08 Oct 2016
Presenter: Karin Bagni
Resources: Abstract
Topic: Pancreatic Cancer

https://oncologypro.esmo.org/Meeting-Resour...derline-resectable-pancreatic-adenocarcinoma

BackgroundNeoadjuvant treatment strategy has been investigated for patients (pts) with borderline resectable pancreatic cancer (BRPC). Although FOLFIRINOX has been more widely used based on its success...

Date: 08 Oct 2016
Presenter: Jihoon Kang
Resources: Abstract
Topics: Anticancer Agents, Pancreatic Cancer, Therapy, Biological Therapy